Einträge von Schnell, Oliver auf dem Publikationsserver

Zeyen, Thomas, Potthoff, Anna-Laura, Nemeth, Robert, Heiland, Dieter H., Burger, Michael C., Steinbach, Joachim P., Hau, Peter, Tabatabai, Ghazaleh, Glas, Martin, Schlegel, Uwe, Grauer, Oliver, Krex, Dietmar, Schnell, Oliver, Goldbrunner, Roland, Sabel, Michael , Thon, Niklas, Delev, Daniel, Clusmann, Hans, Seidel, Clemens, Güresir, Erdem, Schmid, Matthias , Schuss, Patrick , Giordano, Frank A., Radbruch, Alexander, Becker, Albert, Weller, Johannes, Schaub, Christina, Vatter, Hartmut, Schilling, Judith, Winkler, Frank , Herrlinger, Ulrich und Schneider, Matthias (2022) Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial. Trials 23 (1). Volltext nicht vorhanden.

Kamp, Marcel A., Malzkorn, Bastian, von Sass, Christiane, DiMeco, Francesco, Hadjipanayis, Constantinos G., Senft, Christian , Rapp, Marion, Gepfner-Tuma, Irina, Fountas, Konstantinos, Krieg, Sandro M. , Neukirchen, Martin, Florian, Ioan Ștefan, Schnell, Oliver, Mijderwijk, Hendrik-Jan , Perin, Alessandro , Baumgarten, Peter, van Lieshout, Jasper H., Thon, Niklas, Renovanz, Miriam, Kahlert, Ulf, Spoor, Jochem K. H., Hänggi, Daniel, McLean, Aaron Lawson, Mäurer, Matthias, Sarrubbo, Silvio, Freyschlag, Christian F. , Schmidt, Nils O. , Vergani, Francesco, Jungk, Christine, Stein, Marco, Forster, Marie-Therese, Weinberg, Jeffrey S. , Sinclair, John, Belykh, Evgenii, Bello, Lorenzo , Mandonnet, Emmanuel, Moiyadi, Aliasgar und Sabel, Michael (2021) Proposed definition of competencies for surgical neuro-oncology training. Journal of Neuro-Oncology 153 (1), S. 121-131.

Hau, Peter, Dirven, Linda, Luerding, Ralf, Beier, Dagmar, Bumes, Elisabeth, Reinert, Christiane, Seidel, Clemens, Bonsanto, Matteo Mario, Bremer, Michael, Rieken, Stefan, Combs, Stephanie E., Herrlinger, Ulrich, Seliger, Corinna, Kuntze, Holger, Mayer‑Steinacker, Regine, Dieing, Annette, Bartels, Claudius, Schnell, Oliver, Weyerbrock, Astrid, Seidel, Sabine, Grauer, Oliver, Nadji‑Ohl, Minou, Paulsen, Frank , Weller, Michael und Wick, Wolfgang (2020) Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study. Journal of Neuro-Oncology 148, S. 117-130.

Herrlinger, Ulrich, Tzaridis, Theophilos, Mack, Frederic, Steinbach, Joachim Peter, Schlegel, Uwe, Sabel, Michael, Hau, Peter , Kortmann, Rolf-Dieter, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Schnell, Oliver, Bähr, Oliver, Uhl, Martin, Seidel, Clemens, Tabatabai, Ghazaleh , Kowalski, Thomas, Ringel, Florian, Schmidt-Graf, Friederike, Suchorska, Bogdana, Brehmer, Stefanie, Weyerbrock, Astrid, Renovanz, Miriam, Bullinger, Lars, Galldiks, Norbert , Vajkoczy, Peter, Misch, Martin, Vatter, Hartmut, Stuplich, Moritz, Schäfer, Niklas, Kebir, Sied, Weller, Johannes , Schaub, Christina, Stummer, Walter, Tonn, Jörg-Christian, Simon, Matthias, Keil, Vera C., Nelles, Michael, Urbach, Horst, Coenen, Martin, Wick, Wolfgang , Weller, Michael , Fimmers, Rolf, Schmid, Matthias , Hattingen, Elke , Pietsch, Torsten, Coch, Christoph und Glas, Martin (2019) Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial. The Lancet 393 (10172), S. 678-688. Volltext nicht vorhanden.

Schäfer, Niklas, Proescholdt, Martin, Steinbach, Joachim P, Weyerbrock, Astrid, Hau, Peter , Grauer, Oliver, Goldbrunner, Roland, Friedrich, Franziska, Rohde, Veit, Ringel, Florian, Schlegel, Uwe, Sabel, Michael, Ronellenfitsch, Michael W, Uhl, Martin, Grau, Stefan, Hänel, Mathias, Schnell, Oliver, Krex, Dietmar, Vajkoczy, Peter, Tabatabai, Ghazaleh, Mack, Frederic, Schaub, Christina, Tzaridis, Theophilos, Nießen, Michael, Kebir, Sied, Leutgeb, Barbara, Urbach, Horst, Belka, Claus, Stummer, Walter, Glas, Martin und Herrlinger, Ulrich (2017) Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. Neuro-Oncology 20 (7), S. 975-985. Volltext nicht vorhanden.

Herrlinger, Ulrich, Schäfer, Niklas, Steinbach, Joachim P. , Weyerbrock, Astrid, Hau, Peter, Goldbrunner, Roland, Friedrich, Franziska, Rohde, Veit, Ringel, Florian, Schlegel, Uwe, Sabel, Michael, Ronellenfitsch, Michael W. , Uhl, Martin, Maciaczyk, Jaroslaw, Grau, Stefan, Schnell, Oliver, Hänel, Mathias, Krex, Dietmar, Vajkoczy, Peter, Gerlach, Rüdiger, Kortmann, Rolf-Dieter, Mehdorn, Maximilian, Tüttenberg, Jochen, Mayer-Steinacker, Regine, Fietkau, Rainer, Brehmer, Stefanie, Mack, Frederic, Stuplich, Moritz, Kebir, Sied, Kohnen, Ralf, Dunkl, Elmar, Leutgeb, Barbara, Proescholdt, Martin, Pietsch, Torsten, Urbach, Horst, Belka, Claus, Stummer, Walter und Glas, Martin (2016) Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. Journal of Clinical Oncology 34 (14), S. 1611-1619. Volltext nicht vorhanden.

Weller, Michael, Tabatabai, Ghazaleh, Kästner, Bärbel, Felsberg, Jörg, Steinbach, Joachim P., Wick, Antje, Schnell, Oliver, Hau, Peter, Herrlinger, Ulrich, Sabel, Michael C., Wirsching, Hans-Georg, Ketter, Ralf, Bähr, Oliver, Platten, Michael , Tonn, Jörg C., Schlegel, Uwe, Marosi, Christine, Goldbrunner, Roland, Stupp, Roger, Homicsko, Krisztian, Pichler, Josef, Nikkhah, Guido, Meixensberger, Jürgen, Vajkoczy, Peter, Kollias, Spyros, Hüsing, Johannes, Reifenberger, Guido und Wick, Wolfgang (2015) MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Clinical Cancer Research 21 (9), S. 2057-2064. Volltext nicht vorhanden.

Stupp, Roger, Hegi, Monika E , Gorlia, Thierry, Erridge, Sara C, Perry, James, Hong, Yong-Kil, Aldape, Kenneth D, Lhermitte, Benoit, Pietsch, Torsten, Grujicic, Danica, Steinbach, Joachim Peter, Wick, Wolfgang, Tarnawski, Rafał, Nam, Do-Hyun, Hau, Peter, Weyerbrock, Astrid, Taphoorn, Martin J B, Shen, Chiung-Chyi, Rao, Nalini, Thurzo, László, Herrlinger, Ulrich, Gupta, Tejpal, Kortmann, Rolf-Dieter, Adamska, Krystyna, McBain, Catherine, Brandes, Alba A, Tonn, Joerg Christian, Schnell, Oliver, Wiegel, Thomas, Kim, Chae-Yong, Nabors, Louis Burt , Reardon, David A, van den Bent, Martin J , Hicking, Christine, Markivskyy, Andriy, Picard, Martin und Weller, Michael (2014) Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. The Lancet Oncology 15 (10), S. 1100-1108. Volltext nicht vorhanden.